Literature DB >> 32077361

Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.

Raffaele Palmieri1, Sarah A Buckley1, Megan Othus2, Anna B Halpern1,3, Mary-Elizabeth M Percival1,3, Bart L Scott1,4, Paul C Hendrie3,5, Pamela S Becker1,3, Vivian G Oehler1,3, Elihu H Estey1,3, Roland B Walter1,3,6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32077361      PMCID： PMC7384960          DOI： 10.1080/10428194.2020.1728754

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  17 in total

1.  Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Authors:  Anna B Halpern; Megan Othus; Emily M Huebner; Bart L Scott; Paul C Hendrie; Mary-Elizabeth M Percival; Pamela S Becker; Heather A Smith; Vivian G Oehler; Johnnie J Orozco; Ryan D Cassaday; Kelda M Gardner; Tara L Chen; Sarah A Buckley; Kaysey F Orlowski; Asma Anwar; Elihu H Estey; Roland B Walter
Journal:  Haematologica       Date:  2018-11-08       Impact factor: 9.941

2.  Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

Authors:  Joseph M Scandura; Gail J Roboz; Michelle Moh; Ewelina Morawa; Fabienne Brenet; J Robi Bose; Luis Villegas; Usama S Gergis; Sebastian A Mayer; Cindy M Ippoliti; Tania J Curcio; Ellen K Ritchie; Eric J Feldman
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

3.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

Review 4.  Acute myeloid leukemia: 2019 update on risk-stratification and management.

Authors:  Elihu H Estey
Journal:  Am J Hematol       Date:  2018-10       Impact factor: 10.047

5.  A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.

Authors:  A Wrzesień-Kuś; T Robak; A Wierzbowska; E Lech-Marańda; A Pluta; E Wawrzyniak; A Krawczyńska; K Kuliczkowski; G Mazur; M Kiebiński; A Dmoszyńska; M Wach; A Hellmann; W Baran; J Hołowiecki; S Kyrcz-Krzemień; S Grosicki
Journal:  Ann Hematol       Date:  2005-04-27       Impact factor: 3.673

6.  Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.

Authors:  Agnieszka Wierzbowska; Tadeusz Robak; Agnieszka Pluta; Ewa Wawrzyniak; Barbara Cebula; Jerzy Hołowiecki; Sławomira Kyrcz-Krzemień; Sebastian Grosicki; Sebastian Giebel; Aleksander B Skotnicki; Beata Piatkowska-Jakubas; Kazimierz Kuliczkowski; Marek Kiełbiński; Krystyna Zawilska; Janusz Kłoczko; Agata Wrzesień-Kuś
Journal:  Eur J Haematol       Date:  2007-12-11       Impact factor: 2.997

7.  Effect of cytarabine and decitabine in combination in human leukemic cell lines.

Authors:  Taichun Qin; Emile M Youssef; Jaroslav Jelinek; Rong Chen; Allen S Yang; Guillermo Garcia-Manero; Jean-Pierre J Issa
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

8.  Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin.

Authors:  M Kurimoto; H Matsuoka; N Hanaoka; S Uneda; T Murayama; T Sonoki; H Nakakuma
Journal:  Leukemia       Date:  2012-07-03       Impact factor: 11.528

9.  Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Authors:  A B Halpern; M Othus; E M Huebner; S A Buckley; E L Pogosova-Agadjanyan; K F Orlowski; B L Scott; P S Becker; P C Hendrie; T L Chen; M-E M Percival; E H Estey; D L Stirewalt; R B Walter
Journal:  Leukemia       Date:  2017-05-30       Impact factor: 11.528

10.  CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia.

Authors:  Anna B Halpern; Roland B Walter
Journal:  Oncotarget       Date:  2018-11-27
View more
  1 in total

Review 1.  Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5.

Authors:  Xia Gan; Yonghong Liu; Xueni Wang
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.